SCHEMBL26762018

SCHEMBL26762018

COc1cc(C(C)C)cc2cc(Br)c(C)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRNP P04156 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
CRHR1 P34998 1/20 0.44
NQO2 P16083 5/20 0.39
CASR P41180 7/20 0.36
AXL P30530 1/20 0.33
HDAC4 P56524 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
GFER P55789 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
NOD2 Q9HC29 1/20 0.32
P2RX3 P56373 2/20 0.32
P2RX2 Q9UBL9 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26762016 0.84 ALDH1A1 (0.34) PRNPNPSR1ALDH1A1MAPTRXFP1
SCHEMBL26762032 0.81 CRHR1 (0.33) PRNPNPSR1ALDH1A1MAPTRXFP1
SCHEMBL26762022 0.81 ALDH1A1 (0.36) PRNPNPSR1ALDH1A1MAPTRXFP1
SCHEMBL26762020 0.75 ALDH1A1 (0.40) PRNPNPSR1ALDH1A1MAPTRXFP1
SCHEMBL26563693 0.75 ALDH1A1 (0.46) PRNPNPSR1ALDH1A1MAPTRXFP1
SCHEMBL25113960 0.74 CRHR1 (0.40) PRNPNPSR1ALDH1A1MAPTRXFP1
SCHEMBL26108273 0.73 CA12 (0.47) PRNPNPSR1ALDH1A1MAPTRXFP1
SCHEMBL13823638 0.71 CRHR1 (0.51) CRHR1HDAC4HDAC8POLBGAA
SCHEMBL15713187 0.69 HDAC4 (0.42) NPSR1MAPTCRHR1HDAC4HDAC8
SCHEMBL25113827 0.69 HSD17B2 (0.48) PRNPNPSR1ALDH1A1MAPTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365525-A1 ANTIVIRAL COMPOUNDS ENANTA PHARMACEUTICALS, INC. 2023-11-16 US disclosed
US-20230357258-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. 2023-11-09 US disclosed
US-20230357258-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. 2023-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357258-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ACE, HPRT1, ACE2 PRNP 290/4885NPSR1 890/4885ALDH1A1 2104/4885
US-20230365525-A1 ANTIVIRAL COMPOUNDS ACE, ZC3HAV1, SARS1 PRNP 267/4885NPSR1 942/4885ALDH1A1 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.